Replies to post #244313 on Biotech Values

[DewDiligence]

EPIX’s big move yesterday was mainly from (early) clinical—rather than preclinical—data:

https://finance.yahoo.com/news/updated-results-phase-1-2-110000290.html

Cooler heads are prevailing today, so far.